Evidence and experience with onabotulinumtoxinA in chronic migraine: Recommendations for daily clinical practice.
Evidencia y experiencia de bótox en migraña crónica: Recomendaciones para la práctica clínica diaria.
Botulinum neurotoxin A
Chronic migraine
Consenso
Consensus
Guidelines
Migraña crónica
OnabotulinumtoxinA
Preventive treatment
Recomendaciones
Toxina botulínica A
Tratamiento preventivo
Journal
Neurologia
ISSN: 2173-5808
Titre abrégé: Neurologia (Engl Ed)
Pays: Spain
ID NLM: 101778590
Informations de publication
Date de publication:
Historique:
received:
31
08
2017
accepted:
07
09
2017
pubmed:
25
11
2017
medline:
30
1
2020
entrez:
25
11
2017
Statut:
ppublish
Résumé
OnabotulinumtoxinA has been demonstrated to be effective as a preventive treatment in patients with chronic migraine (CM). Five years after the approval of onabotulinumtoxinA in Spain, the Headache Study Group of the Spanish Society of Neurology considered it worthwhile to gather a group of experts in treating patients with CM in order to draw up, based on current evidence and our own experience, a series of guidelines aimed at facilitating the use of the drug in daily clinical practice. For this purpose, we posed 12 questions that we ask ourselves as doctors, and which we are also asked by our patients. Each author responded to one question, and the document was then reviewed by everyone. We hope that this review will constitute a practical tool to help neurologists treating patients with CM.
Identifiants
pubmed: 29169810
pii: S0213-4853(17)30324-9
doi: 10.1016/j.nrl.2017.09.008
pii:
doi:
Substances chimiques
Botulinum Toxins, Type A
EC 3.4.24.69
onabotulinum toxin A
EC 3.4.24.69
Types de publication
Journal Article
Review
Langues
eng
spa
Sous-ensembles de citation
IM
Pagination
408-417Informations de copyright
Copyright © 2017 Sociedad Española de Neurología. Publicado por Elsevier España, S.L.U. All rights reserved.